| DeJongste 1994 | Hauvast 1998 | Eddicks 2007 | ESBY 1998 | SpiRiT 2006 |
---|---|---|---|---|---|
Follow up | 13.8 months | 6-weeks | 4 weeks | 2-years | 1-year |
SCS-related complication | |||||
Infection | NR | 0/13 | NR | 1/57 | 0/34 |
Lead migration/fracture | 6/34 | 0/13 | NR | 3/57 | 1/34 |
Mortality/morbidity | |||||
Non fatal MI | 1/12 | NR | NR | SCS 7/53 CABG 3/53, P = 0.18 | SCS 4/34 PMR 1/34, P = 0.16 |
Total mortality | 2/12 | NR | NR | SCS 5/53 CABG 10/53, P = 0.16 | SCS 4/34 PMR 2/34, P = 0.73 |
Cardiac mortality | 2/12 | NR | NR | SCS 3/53 CABG 5/53, P = 0.54 | SCS 2/34 PMR 1/34, P = 0.52 |
Other outcomes | |||||
Treatment cross over | NR | NR | NR | 6-months SCS 3/53 CABG 3/51 | SCS 1/34 PMR 0/33 |